Regeneron Initial Data on Multiple Myeloma Drug Encouraging

Regeneron Pharmaceuticals, Inc. (REGN) announced encouraging initial results from two cohorts of the early-stage study on oncology drug linvoseltamab.LINKER-MM2 is a phase Ib, open-label clinical trial evaluating linvoseltamab in combination with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM).  Results presented that linvoseltamab in combination with carfilzomib or bortezomib showed promising results in earlier lines of treatment for relapsed/refractory multiple mye ...